drugset / Trial / NCT00272844

Treatment of the Cholesterol Defect in Smith-Lemli-Opitz Syndrome

NCT00272844

Phase 1/2 Completed 23 enrolled Boston Children's Hospital
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether supplementation with an oil-based cholesterol suspension will correct the biochemical abnormalities in cholesterol and its precursors in individuals with the Smith-Lemli-Opitz syndrome.

Timeline

Start
1998-01
Primary completion
2011-06
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Cholesterol Small molecule 75 mg/kg
Subject Cholesterol Small molecule 300 mg/kg